Development of a general method of limited sampling for the determination of AUC for a drug that displays two-compartment pharmacokinetics

European Journal of Clinical Pharmacology

Volumn 55, Issue 3, 1999, Pages 213-219

  Duffull, S B ^a,c   Begg, E J ^a   Deely, J J ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF CANTERBURY   (New Zealand)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Area under the curve; Limited sampling; Pharmacokinetics

Indexed keywords

UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG METABOLISM; PRIORITY JOURNAL; SIMULATION;

AREA UNDER CURVE; HUMANS; MODELS, BIOLOGICAL;

EID: 0033016370     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050620     Document Type: Article

References (18)

1. 1. Landaw EM (1985) Optimal design for individual parameter estimation in pharmacokinetics. In: Rowland M, Sheiner LB, Steimer JL (eds) Variability in drug therapy: description, estimation and control. Raven Press, New York, pp 187-199
2. 2. D'Argenio DZ (1981) Optimal sampling times for pharmacokinetic experiments. J Pharmacokin Biopharm 9: 739-756
3. 3. Dell RB, Ramakrishnan R, Palmer RH, Goodman DS (1985) A convenient six-point blood sampling schedule for determining whole body cholesterol kinetics in humans. J Lipid Res 26: 575-582
4. 4. Sørensen BT, Strömgren A, Jakobsen P, Jakobsen A (1993) A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31: 324-327
5. 5. Ghazal-Aswad S, Calvert AH, Newell DR (1996) A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 37: 429-434
6. 6. Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA (1989) A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 49: 3129-3133
7. 7. Moore MJ, Bunting P, Yuan S, Thiessen JJ (1993) Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration. Ther Drug Monit 15: 394-399
8. 8. Regazzi MB, Rondanelli R, Gastaldi L, Martinelli L, Vigano M (1992) Optimization of sampling time for cyclosporine monitoring in transplant patients. J Clin Pharmacol 32: 978-981
9. 9. Balis FM, Pizzo PA, Butler KM, Hawkins ME, Brouwers P, Husson RN, Jacobsen F, Blaney SM, Gress J, Jarosinski P, Poplack DG (1992) Clinical pharmacology of 2′,3′-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 165: 99-104
10. 10. Ratain MJ, Staubus AE, Schilsky RL, Malspeis, L (1988) Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res 48: 4127-4130
11. 11. Eksborg S, Albertioni F, Beck O, Peterson C, Seideman P (1994) Methotrexate in rheumatoid arthritis - a limited sampling strategy for estimation of the area under the plasma concentration versus time curve. Ther Drug Monit 16: 560-563
12. 12. Launay MC, Milano G, Iliadis A, Frenay M, Namer N (1989) A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients. Br J Cancer 60: 89-92
13. 13. Ette EI, Kelman AW, Howie CA, Whiting B (1993) Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters. Ann Pharmacother 27: 1034-1039
14. 14. Rowland M, Tozer TN (1995) Clinical Pharmacokinetics. Concepts and Application. Third edition, Williams & Wilkins London
15. 15. Duffull SB, Robinson BA (1997) Clinical pharmacokinetics and dose optimisation of carboplatin. Clin Pharmacokinet 33: 161-183
16. 16. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokin Biopharm 9: 503-513
17. 17. Sallas WM (1995) Development of limited sampling strategies for characteristics of a pharmacokinetic profile. J Pharmacokin Biopharm 23: 515-529
18. 18. Tod M, Padoin C, Louchahi K, Moreau-Tod B, Petitjean O, Perret G (1994) Application of optimal sampling theory to the determination of metacycline pharmacokinetic parameters: effect of model misspecification. J Pharmacokin Biopharm 22: 129-146